Healthcare Industry News: drug-eluting stent
News Release - March 22, 2007
Angiotech appoints Santi Corsaro Vice President, Sales and Marketing OUSVANCOUVER, March 22 (HSMN NewsFeed) - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the appointment of Santi Corsaro as Vice President, Sales and Marketing OUS.
With his considerable experience in the health care industry, including direct experience in wound closure, medical device and drug-eluting stent markets, Dr. Corsaro brings to Angiotech his extensive sales and marketing expertise gained from his senior roles at multinational corporations in Europe.
"We are pleased to announce this important hire for Angiotech, which sets the groundwork for growth of our key products in Europe, including the VaxSys Synergy® and Quill® SRS product lines. We believe that our ability to attract this calibre of talent is further evidence of the validity of our long-term business and commercialization strategy," said Dr. William Hunter, President and CEO of Angiotech.
As Vice President, Sales and Marketing OUS, Dr. Corsaro will oversee Angiotech's European commercial operations. It is anticipated that he will lend his experience to initiate a profitable growth strategy on a country-by-country basis, build local sales organizations and marketing teams, and establish direct sales subsidiaries in key European countries.
Prior to joining Angiotech, Dr. Corsaro spent over 20 years working for the Johnson & Johnson (J&J) Group in Europe. Most recently, Dr. Corsaro was President and Managing Director of J&J Medical Holding SpA Italy, where he was responsible for merging four different J&J organizations under a single legal entity. Prior to this, Dr. Corsaro was the European President of Cordis, a subsidiary of J&J, where he managed 300 employees and was responsible for reorganizing the European Cordis structure and increasing drug-eluting stent adoption rates. Dr. Corsaro was also Worldwide President for J&J's A.S.P. (Advanced Sterilization Products) Company. At J&J's Ethicon Division, Dr. Corsaro held a series of increasingly senior positions culminating with his role as European President, Ethicon Endo Surgery based in Hamburg, Germany, where he managed 570 employees with direct reporting countries of the UK, Germany, France, Italy and provided marketing support to all other European countries.
Note on Forward Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following; general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include; poor performance of the product in the clinical setting; adverse events related to the use of the product; improper estimation of the size of the product markets; adverse results or unexpected delays in clinical development processes; our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; our ability to continue to integrate into our business the operations of American Medical Instruments Holdings, Inc. and our ability to achieve the operational and other synergies and the other commercial or financial benefits expected as a result of that acquisition; and any other factors referenced in our annual information form and other filings with the applicable Canadian securities regulatory authorities or the SEC.
Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this prospectus to reflect future results, events or developments.
Angiotech® and VaxSys Synergy(TM) are trademarks of Angiotech Pharmaceuticals, Inc.
Quill® is a registered trademark of Quill Medical, Inc., a wholly-owned subsidiary of Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with 17 facilities in 6 countries and over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at www.angiotech.com.
Source: Angiotech Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.